Recent data indicate that genetic variations in FCGR2, the gene coding for FcγRIIb, affect the efficacy of IVIg in CIDP [68] as discussed later, supporting the importance of FcγRIIb in IVIg effectiveness. The gene discussed is FCGR2B; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.